Chairperson: Peter A. Jones, Ph.D., D.Sc. University of Southern California, Los Angeles, CA
Increasingly, the field of epigenomics is making important contributions to cancer research and treatment. This task force seeks to discover innovative strategies for applying today's best science to this exciting research area, which holds promise for major advances in cancer treatment and prevention, and for other diseases as well. The goals of the task force are to: (1) finalize the approximate number of epigenomes to be defined at high resolution; (2) specify which histone modification marks should be included in the initial definition of the epigenome; (3) constitute subcommittees to discuss specific tissues which could be investigated at a high level of definition; (4) define a series of tissues and pathological states, such as cancer, which could be investigated at a lower level of resolution with respect to histone modification marks and DNA cytosine methylation patterns; (5) develop cost estimates and stages for the project, based on current and anticipated technology, including emerging sequencing platforms; and (6) develop a timetable for the implementation of an Alliance for the Human Epigenome and Disease (AHEAD) Project.
Read the Special Report on the AACR Human Epigenome Workshop.
Read the Task Force's Proposal for an International AHEAD Pilot Project.
Membership of the Human Epigenome Task Force
Peter A. Jones, Ph.D., D.Sc., Chairperson
Director
University of Southern California/Norris Comprehensive Cancer Center
Los Angeles, CA
Trevor K. Archer, Ph.D.
Principal Investigator and Chief, Laboratory of Molecular Carcinogenesis
NIH-NIEHS
Research Triangle Park, NC
Stephen B. Baylin, M.D.
Professor of Oncology and Chief, Cancer Biology Division
Johns Hopkins University School of Medicine
Baltimore, MD
Stephan Beck, Ph.D.
Professor of Medical Genomics
UCL Cancer Institute
London, England
Shelley Berger, Ph.D.
H. Koprowski Professor of Gene Expression and Regulation
The Wistar Institute
Philadelphia, PA
Bradley E. Bernstein, M.D., Ph.D.
Assistant Professor, Department of Pathology
Massachusetts General Hospital
Charleston, MA
John D. Carpten, Ph.D.
Senior Investigator and Director, Integrated Cancer Genomics Division
TGen
Phoenix, AZ
Susan J. Clark , Ph.D.
Associate Professor
Garvan Institute of Medical Research
Sydney, Australia
Joseph F. Costello, Ph.D.
Assistant Professor, Department of Neurological Surgery
University of California, San Francisco
San Francisco, CA
Rebecca W. Doerge, Ph.D.
Professor, Departments of Agronomy and Statistics
Purdue University
West Lafayette, IN
Manel Esteller, M.D., Ph.D.
Laboratory Director, Cancer Epigenetics Group
Spanish National Cancer Center
Madrid, Spain
Andrew P. Feinberg, M.D.
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Thomas R. Gingeras, Ph.D.
Vice President of Biological Sciences
Affymetrix, Inc.
Santa Clara, CA
John M. Greally, M.B., B.Ch., Ph.D.
Associate Professor, Departments of Medicine and Molecular Genetics
Albert Einstein College of Medicine
Bronx, NY
Steven Henikoff, Ph.D.
Member, Basic Sciences Division
Howard Hughes Medical Institute Investigator
Fred Hutchinson Cancer Research Center
Seattle, WA
James G. Herman, M.D.
Associate Professor
Johns Hopkins University School of Medicine
Baltimore, MD
Laurie Jackson-Grusby, Ph.D.
Assistant Professor, Department of Pathology
Harvard Medical School
Boston, MA
Thomas Jenuwein, Ph.D.
Senior Scientist
Research Institute of Molecular Pathology
Vienna, Austria
Randy L. Jirtle, Ph.D.
Professor, Department of Radiation Oncology
Duke University Medical Center
Durham, NC
Young-Joon Kim, Dr.P.H.
Yonsei University
Seoul, Korea
Peter W. Laird, Ph.D.
Associate Professor, Biochemistry & Molecular Biology
University of Southern California
Los Angeles, CA
Bing Lim, M.D., Ph.D., FRCP(C)
Senior Group Leader and Associate Director of Biology
Genome Institute of Singapore
Genome, Singapore
Robert Martienssen, Ph.D.
Professor
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
Kornelia Polyak, M.D., Ph.D.
Associate Professor, Department of Medicine
Dana-Farber Cancer Institute
Boston, MA
Henk Stunnenberg, Ph.D.
Head, Department of Molecular Biology
Radboud University Nijmegen
GA Nijmegen, Netherlands
Thea Dorothy Tlsty, Ph.D.
Professor, Department of Pathology
University of California, San Francisco
San Francisco, CA
Benjamin Tycko, M.D., Ph.D.
Associate Professor, Institute for Cancer Genetics
Columbia University
New York, NY
Toshikazu Ushijima, M.D., Ph.D.
Chief, Carcinogenesis Division
National Cancer Center Research Institute
Tokyo, Japan
Jingde Zhu, Ph.D.
Principal Investigator, Biochemistry and Molecular Biology
Shanghai Cancer Institute
Shanghai, China
Staff contact: Kimberly A. Sabelko, Ph.D., Senior Program Administrator, Executive Office (kimberly.sabelko@aacr.org or 215-440-9300).